Compare · ABUS vs ROIV
ABUS vs ROIV
Side-by-side comparison of Arbutus Biopharma Corporation (ABUS) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABUS and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ROIV is the larger of the two at $22.61B, about 25.2x ABUS ($898.8M).
- Over the past year, ABUS is up 33.4% and ROIV is up 173.0% - ROIV leads by 139.6 points.
- ABUS has hit the wire 3 times in the past 4 weeks while ROIV has been quiet.
- ROIV has more recent analyst coverage (18 ratings vs 3 for ABUS).
- Company
- Arbutus Biopharma Corporation
- Roivant Sciences Ltd.
- Price
- $4.55+2.71%
- $31.40+0.67%
- Market cap
- $898.8M
- $22.61B
- 1M return
- +8.59%
- +11.35%
- 1Y return
- +33.43%
- +173.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 0
- Recent ratings
- 3
- 18
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical trial collaboration agreement with Vaccitech plc to evaluate a therapeutic combination for the treatment of subjects with chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ABUS
- SEC Form 4 filed by Director Sawhney Roger
- SEC Form 4 filed by Director Beardsley Robert A
- SEC Form S-8 filed by Arbutus Biopharma Corporation
- Arbutus Biopharma Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Arbutus Biopharma Corporation
- Arbutus Biopharma Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
- SEC Form DEFA14A filed by Arbutus Biopharma Corporation
Latest ROIV
- President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)
- CFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax
- SEC Form S-8 filed by Roivant Sciences Ltd.
- SEC Form 10-K filed by Roivant Sciences Ltd.
- Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
- Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.